Human CCL3/MIP-1 alpha Quantikine ELISA Kit
| Name | Human CCL3/MIP-1 alpha Quantikine ELISA Kit |
|---|---|
| Supplier | R&D Systems |
| Catalog | DMA00 |
| Category | ELISA Kit |
| Prices | $479.00, $2,290.00, $15,560.00 |
| Sizes | 1 kit, 1 pack (6 Plates), 1 pack (50 Plates) |
| Assay Type | Solid Phase Sandwich ELISA |
| Sample Type | Cell Culture Supernates (10 uL), Serum (200 uL), EDTA Plasma (200 uL), Heparin Plasma (200 uL), Citrate Plasma (200 uL) |
| Sensitivity | 10 pg/mL |
| Range | 31.2 - 1,000 pg/mL (Cell Culture Supernates), 46.9 - 1,500 pg/mL (Serum, EDTA Plasma, Heparin Plasma, Citrate Plasma) |
| Format | 96-well strip plate |
| Applications | ELISA |
| Species Reactivities | Human |
| Description | The Quantikine Human MIP-1 alpha Immunoassay is a 3.5 or 4.5 hour solid phase ELISA designed to measure MIP-1 alpha levels in cell culture supernates, serum, and plasma |
| Gene | CCL3 |
| Supplier Page | Shop |
Product images
Product References
Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic - Functional Differences between IgM and IgD Signaling in Chronic Lymphocytic
Ten Hacken E, Sivina M, Kim E, O'Brien S, Wierda WG, Ferrajoli A, Estrov Z, Keating MJ, Oellerich T, Scielzo C, Ghia P, Caligaris-Cappio F, Burger JA. J Immunol. 2016 Sep 15;197(6):2522-31.
The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145 - The phosphoinositide-3-kinase (PI3K)-delta and gamma inhibitor, IPI-145
Balakrishnan K, Peluso M, Fu M, Rosin NY, Burger JA, Wierda WG, Keating MJ, Faia K, O'Brien S, Kutok JL, Gandhi V. Leukemia. 2015 Sep;29(9):1811-22.
Low concentrations of recombinant granulocyte macrophage-colony stimulating - Low concentrations of recombinant granulocyte macrophage-colony stimulating
Hashimoto A, Tanaka T, Itoh Y, Yamagata A, Kitamura N, Tazawa R, Nakagaki K, Nakata K. Cytokine. 2014 Aug;68(2):118-26.
Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to - Respiratory syncytial virus glycoprotein G interacts with DC-SIGN and L-SIGN to
Johnson TR, McLellan JS, Graham BS. J Virol. 2012 Feb;86(3):1339-47.
The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic - The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic
Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, Keating MJ, O'Brien S, Chiorazzi N, Burger JA. Blood. 2012 Feb 2;119(5):1182-9.
Alveolar fibrocyte percentage is an independent predictor of poor outcome in - Alveolar fibrocyte percentage is an independent predictor of poor outcome in
Quesnel C, Piednoir P, Gelly J, Nardelli L, Garnier M, Lecon V, Lasocki S, Bouadma L, Philip I, Elbim C, Mentre F, Soler P, Crestani B, Dehoux M. Crit Care Med. 2012 Jan;40(1):21-8.
CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic - CCL3 (MIP-1alpha) plasma levels and the risk for disease progression in chronic
Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, LaPushin R, Xiao L, Huang X, Werner L, Neuberg D, Kantarjian H, O'Brien S, Wierda WG, Keating MJ, Rosenwald A, Burger JA. Blood. 2011 Feb 3;117(5):1662-9.
A phase I trial of bortezomib with temozolomide in patients with advanced - A phase I trial of bortezomib with temozolomide in patients with advanced
Su Y, Amiri KI, Horton LW, Yu Y, Ayers GD, Koehler E, Kelley MC, Puzanov I, Richmond A, Sosman JA. Clin Cancer Res. 2010 Jan 1;16(1):348-57.
HIV increases markers of cardiovascular risk: results from a randomized, - HIV increases markers of cardiovascular risk: results from a randomized,
Calmy A, Gayet-Ageron A, Montecucco F, Nguyen A, Mach F, Burger F, Ubolyam S, Carr A, Ruxungtham K, Hirschel B, Ananworanich J. AIDS. 2009 May 15;23(8):929-39.
Interleukin-32 promotes osteoclast differentiation but not osteoclast activation. - Interleukin-32 promotes osteoclast differentiation but not osteoclast activation.
Mabilleau G, Sabokbar A. PLoS One. 2009;4(1):e4173.